查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1638786

抗心律不整药物市场机会、成长动力、产业趋势分析及 2024 年至 2032 年预测

Antiarrhythmic Drugs Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 to 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 150 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2023 年，全球抗心律不整药物市场价值约为10 亿美元，预计2024 年至2032 年复合年增长率为6%。失常或心律不整至关重要。抗心律不整药物可治疗一系列疾病，包括心房颤动和心室心搏过速，以帮助维持心血管稳定性。

根据药物类型，β 受体阻断剂领域的市场在2023 年以3.264 亿美元的收入领先市场。它们对于长期健康至关重要。它们在调节心律和控制血压方面的有效性凸显了它们在心血管护理中不可或缺的作用。

依疾病类型划分，市场涵盖室性心律不整、室上性心律不整等。 2023年，室性心律不整领域的收入最高，达4.297亿美元。全球心血管疾病，尤其是室性心律不整的增加，凸显了有效抗心律不整治疗的必要性。药物配方和输送系统的进步增强了治疗效果，而副作用减少的下一代抗心律不整药物则支持了细分市场的成长。

市场范围
开始年份 2023年
预测年份 2024-2032
起始值 10亿美元
预测值 17亿美元
复合年增长率 6%

2023 年，美国抗心律不整药物市场达到 4.205 亿美元，预计在预测期内复合年增长率为 6.1%。推动这一增长的一个重要因素是人口老化，这增加了对心臟护理的需求。美国食品药物管理局 (FDA) 的监管支持促进了创新疗法的批准和推出，促进了市场扩张。此外，美国是药品研发的主要中心，在抗心律不整药物开发方面投入了大量资金。正在进行的临床试验和研究准备将先进的疗法推向市场，进一步支持成长。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 心律不整的盛行率增加
      • 抗心律不整药物研发进展
      • 提高认识并改善诊断
    • 产业陷阱与挑战
      • 潜在的严重副作用
      • 对非药物治疗的偏好日益增加
  • 成长潜力分析
  • 监管环境
  • 技术景观
    • 核心技术
    • 邻近技术
  • 未来市场趋势
  • 专利分析
  • 管道分析
  • 临床试验情况
  • 差距分析
  • 波特的分析
  • PESTEL分析

第 4 章：竞争格局

  • 介绍
  • 公司市占率分析
  • 公司矩阵分析
  • 主要市场参与者的竞争分析
  • 竞争定位矩阵
  • 战略仪表板

第 5 章：市场估计与预测：按药物类型，2021 - 2032

  • 主要趋势
  • 钠通道阻断剂（I 级）
  • β 受体阻断剂（II 型）
  • 钾通道阻断剂（III 类）
  • 钙通道阻断剂（IV 类）
  • 其他药物类型

第 6 章：市场估计与预测：按疾病类型，2021 - 2032

  • 主要趋势
  • 室性心律不整
  • 室上性心律不整
  • 其他疾病类型

第 7 章：市场估计与预测：按管理途径，2021 - 2032 年

  • 主要趋势
  • 口服
  • 可注射
  • 其他给药途径

第 8 章：市场估计与预测：按配销通路，2021 - 2032 年

  • 主要趋势
  • 医院药房
  • 零售药局
  • 电子商务
  • 其他分销管道

第 9 章：市场估计与预测：按地区划分，2021 - 2032 年

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 荷兰
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第 10 章：公司简介

  • Abbott Laboratories
  • Astellas Pharma
  • AstraZeneca
  • Baxter International
  • Bayer AG
  • Bristol-Myers Squibb
  • GlaxoSmithKline
  • Johnson & Johnson
  • Milestone Pharmaceuticals
  • Novartis International
  • Pfizer
  • Sanofi
  • Teva Pharmaceutical Industries
  • Upsher-Smith Laboratories
  • Viatris
简介目录
Product Code: 12134

The Global Antiarrhythmic Drugs Market was valued at approximately USD 1 billion in 2023 and is anticipated to expand at a CAGR of 6% from 2024 to 2032. These medications are essential for managing arrhythmias, or irregular heart rhythms, by modifying the heart's electrical conduction to restore normal rhythm. Antiarrhythmic drugs address a range of conditions, including atrial fibrillation and ventricular tachycardia, to help maintain cardiovascular stability.

Based on drug type, the market from the beta blockers segment led the market with USD 326.4 million in revenue in 2023. The growing prevalence of cardiovascular conditions such as hypertension and arrhythmias is fueling demand for beta blockers, as they are critical for the long-term management and treatment of these disorders. Their effectiveness in regulating heart rhythm and managing blood pressure highlights their integral role in cardiovascular care.

By disease type, the market covers ventricular arrhythmias, supraventricular arrhythmias, and others. In 2023, the ventricular arrhythmias segment held the highest revenue, reaching USD 429.7 million. The global rise in cardiovascular diseases, especially ventricular arrhythmias, underscores the need for effective antiarrhythmic treatments. Advances in drug formulation and delivery systems enhance treatment outcomes, while next-generation antiarrhythmic drugs with reduced side effects support segment growth.

Market Scope
Start Year2023
Forecast Year2024-2032
Start Value$1 Billion
Forecast Value$1.7 Billion
CAGR6%

The U.S. antiarrhythmic drugs market reached USD 420.5 million in 2023, projected growth at a 6.1% CAGR through the forecast period. A significant factor driving this growth is the aging population, which increases the demand for cardiac care. Regulatory support from the U.S. Food and Drug Administration (FDA) facilitates the approval and introduction of innovative therapies, fostering market expansion. Additionally, the U.S. is a major hub for pharmaceutical R&D, with substantial investments in antiarrhythmic drug development. Ongoing clinical trials and research are poised to bring advanced therapies to the market, further supporting growth.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing prevalence of cardiac arrhythmias
      • 3.2.1.2 Advancements in antiarrhythmic drug development
      • 3.2.1.3 Rising awareness and improved diagnosis
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 Potential for severe side effects
      • 3.2.2.2 Growing preference for non-pharmacological treatments
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Technological landscape
    • 3.5.1 Core technologies
    • 3.5.2 Adjacent technologies
  • 3.6 Future market trends
  • 3.7 Patent analysis
  • 3.8 Pipeline analysis
  • 3.9 Clinical trial landscape
  • 3.10 Gap analysis
  • 3.11 Porter's analysis
  • 3.12 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Sodium channel blockers (Class I)
  • 5.3 Beta blockers (Class II)
  • 5.4 Potassium channel blockers (Class III)
  • 5.5 Calcium channel blockers (Class IV)
  • 5.6 Other drug types

Chapter 6 Market Estimates and Forecast, By Disease Type, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Ventricular arrhythmias
  • 6.3 Supraventricular arrhythmias
  • 6.4 Other disease types

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Oral
  • 7.3 Injectable
  • 7.4 Other routes of administration

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospital pharmacies
  • 8.3 Retail pharmacies
  • 8.4 E-commerce
  • 8.5 Other distribution channels

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Netherlands
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE

Chapter 10 Company Profiles

  • 10.1 Abbott Laboratories
  • 10.2 Astellas Pharma
  • 10.3 AstraZeneca
  • 10.4 Baxter International
  • 10.5 Bayer AG
  • 10.6 Bristol-Myers Squibb
  • 10.7 GlaxoSmithKline
  • 10.8 Johnson & Johnson
  • 10.9 Milestone Pharmaceuticals
  • 10.10 Novartis International
  • 10.11 Pfizer
  • 10.12 Sanofi
  • 10.13 Teva Pharmaceutical Industries
  • 10.14 Upsher-Smith Laboratories
  • 10.15 Viatris